Patient Subgroup Analysis of Quality-of-Life Outcomes in Checkmate 205, a Phase 2 Study of Nivolumab in Patients with Classical Hodgkin Lymphoma

被引：0
|
作者：
Engert, Andreas [1 ]
Taylor, Fiona [2 ]
Bennett, Bryan [3 ]
Hirji, Ishan [4 ]
Cocks, Kim [3 ]
McDonald, Jeffrey [2 ]
Mann, Erin [2 ]
Kato, Kazunobu [4 ]
Cella, David [5 ]
机构：
[1] Univ Hosp Cologne, Cologne, Germany
[2] Adelphi Values, Boston, MA USA
[3] Adelphi Values, Bollington, England
[4] Bristol Myers Squibb Co, Princeton, NJ USA
[5] Northwestern Univ, Evanston, IL 60208 USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.1831.1831
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1831
引用
收藏
页数：6
相关论文
共 50 条
  • [1] QUALITY-OF-LIFE OUTCOMES IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA TREATED WITH NIVOLUMAB MONOTHERAPY IN CHECKMATE 205 (COHORT B), A PHASE 2 STUDY
    Engert, A.
    Hirji, I.
    Taylor, F.
    Bennett, B.
    Cocks, K.
    Kato, K.
    Cella, D.
    HAEMATOLOGICA, 2016, 101 : 73 - 73
  • [2] CHECKMATE 205: A PHASE 2 STUDY OF NIVOLUMAB IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA FOLLOWING AUTOLOGOUS STEM CELL TRANSPLANTATION AND BRENTUXIMAB VEDOTIN
    Engert, A.
    Santoro, A.
    Shipp, M.
    Zinzani, P. L.
    Timmerman, J.
    Ansell, S.
    Armand, P.
    Fanale, M.
    Ratanatharathorn, V.
    Kuruvilla, J.
    Cohen, J.
    Collins, G.
    Savage, K.
    Trneny, M.
    Kato, K.
    Farsaci, B.
    Parker, S.
    Rodig, S.
    Younes, A.
    HAEMATOLOGICA, 2016, 101 : 319 - 319
  • [3] Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 Checkmate 205 Study
    Cohen, Jonathon B.
    Engert, Andreas
    Ansell, Stephen M.
    Younes, Anas
    Trneny, Marek
    Savage, Kerry J.
    Ramchandren, Radhakrishnan
    Collins, Graham
    Fanale, Michelle A.
    Armand, Philippe
    Zinzani, Pier Luigi
    De Boer, Jan Paul
    Shipp, Margaret A.
    Santoro, Armando
    Timmerman, John M.
    Sacchi, Mariana
    Sy, Oumar
    Kuruvilla, John
    BLOOD, 2017, 130
  • [4] Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma From the Phase 2 CheckMate 205 Study
    Cohen, J. B.
    Engert, A.
    Ansell, S. M.
    Younes, A.
    Trneny, M.
    Savage, K. J.
    Ramchandren, R.
    Collins, G. P.
    Fanale, M. A.
    Armand, P.
    Zinzani, P. L.
    de Boer, J. P.
    Shipp, M. A.
    Santoro, A.
    Timmerman, J. M.
    Sacchi, M.
    Sy, O.
    Kuruvilla, J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 87 - 88
  • [5] Effect of Nivolumab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma after Autologous Transplantation: Results from the Multicohort Phase 2 Checkmate 205 Study
    Engert, Andreas
    Taylor, Fiona
    Bennett, Bryan
    Chen, Clara
    Cocks, Kim
    McDonald, Jeffrey
    Mann, Erin
    Sacchi, Mariana
    Cella, David
    BLOOD, 2017, 130
  • [6] Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study
    Ramchandren, Radhakrishnan
    Fanale, Michelle A.
    Rueda, Antonio
    Armand, Philippe
    Trneny, Marek
    Feldman, Tatyana A.
    Ansell, Stephen M.
    Provencio, Mariano
    Jaeger, Ulrich
    Cohen, Jonathon B.
    Savage, Kerry J.
    Willenbacher, Wolfgang
    Sacchi, Mariana
    Sumbul, Anne
    Domenech, Eva Domingo
    BLOOD, 2017, 130
  • [7] Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study
    Ansell, Stephen M.
    Brockelmann, Paul J.
    von Keudell, Gottfried
    Lee, Hun Ju
    Santoro, Armando
    Zinzani, Pier Luigi
    Collins, Graham P.
    Cohen, Jonathon B.
    de Boer, Jan Paul
    Kuruvilla, John
    Savage, Kerry J.
    Trneny, Marek
    Provencio, Mariano
    Jaeger, Ulrich
    Willenbacher, Wolfgang
    Wen, Rachael
    Akyol, Alev
    Mikita-Geoffroy, Joanna
    Shipp, Margaret A.
    Engert, Andreas
    Armand, Philippe
    BLOOD ADVANCES, 2023, 7 (20) : 6266 - 6274
  • [8] Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma
    Timmerman, John M.
    Engert, Andreas
    Younes, Anas
    Santoro, Armando
    Armand, Philippe
    Fanale, Michelle A.
    Collins, Graham P.
    Ratanatharathorn, Voravit
    Kuruvilla, John
    Cohen, Jonathon B.
    Savage, Kerry J.
    Trneny, Marek
    De Boer, Jan Paul
    Shipp, Margaret A.
    Rodig, Scott J.
    Kato, Kazunobu
    Sumbul, Anne
    Ansell, Stephen
    BLOOD, 2016, 128 (22)
  • [9] Nivolumab in Classical HL: Results From the Phase 2 CheckMate 205 Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (02) : 17 - 20
  • [10] TREATMENT-RELATED ADVERSE EVENTS WITH NIVOLUMAB IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: RESULTS FROM A COHORT ANALYSIS OF THE PHASE 2 CHECKMATE 205 STUDY.
    Wesson, Emily
    Klebig, Robin
    Stephans, Katherine
    Palmer, Alexandra
    Kurosky, Alanna
    Copeland, Amanda
    ONCOLOGY NURSING FORUM, 2017, 44 (02)
12345